Pharma BD Deal Intelligence

Ipsen SA / Inspiration Biopharmaceuticals, Inc.

2010 · Co-Development · $259M · Terminated

Ipsen and Inspiration Biopharmaceuticals hemophilia partnership: Ipsen took 20% stake for $85M, plus up to $174M for additional 27% stake based on milestones (total $259M). Inspiration later filed Chapter 11 in 2012.

Key facts

• Announced Aug 12, 2010
• Deal value $259M
• Deal type Co-Development
• Therapeutic area Hemophilia A with inhibitors; hemophilia B
• Indications Hemophilia A with inhibitors; hemophilia B
• Key assets OBI-1 (recombinant porcine factor VIII); IB1001 (recombinant factor IX)
• Mechanism Recombinant clotting factor replacement

← Browse all deals  ·  How we score deals